VIKING-MALT-GROUP
30.8.2021 14:43:06 CEST | Business Wire | Press release
Marcin Siemion has decided to leave the Viking Malt Group. He has over many years successfully developed the Viking Malt Polish business and been a key contributor to creating a strong commercial position for Viking Malt Group in the international malting industry. We thank him for his contribution to the company and wish him all the best both privately and professionally. Following this, we would like to announce the following changes in Viking Malt Sales organization:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005352/en/
Malin Andersson has been appointed VP Sales in Viking Malt Group
Malin Andersson will be responsible for the sales strategy and the volume customers. She will become a member of the Group Management Team and in her role help Viking Malt in its mission of providing value-adding malted products to our customers for their success. Malin has been with the company since 1997, successfully leading sales, marketing, customer service and logistics in Viking Malt Sweden as well as had the role of a Site Manager and as latest also the role of Managing Director of Viking Malt Sweden. She has in depth knowledge of the company and the industry with a wide international network in malting and brewing industry. She holds an Executive MBA from Copenhagen Business School.
Annika Wilhelmson will lead the Craft and Partner Sales
At the same time, we have the pleasure to announce that Annika Wilhelmson will be responsible for the Craft and Partner Sales and Marketing. She will continue her work in the Group Management Team and cover Innovation, Quality and CSR in the Vice President role. Annika started with Viking Malt Group in 2017 as VP New Business Development. She holds a doctor´s degree in chemical engineering from Helsinki University of Technology and is specialized in malting. Prior to Viking Malt she has worked at VTT in several roles including senior scientist, project manager and Key Account Manager responsible for sales.
Tomasz Malec appointed Viking Malt Poland Managing Director
VP Supply Chain Tomasz Malec will take over the role of the MD of the Viking Malt Polish entity. He continues in his role as the VP Supply Chain and as the member of the Management Team for the Group.
Before Viking Malt Tomasz Malec worked for Carlsberg for almost twenty years, latest as the VP Production for Carlsberg Poland. Prior to Carlsberg he has worked for Elkometech, Danfoss and Computerland SA as well as Huta Auluminimum Konin SA in different roles. Tomasz holds a degree in engineering from Łódź Technical University, Poland.
“I am delighted to offer these important roles to three of our key leaders. I feel confident that we will continue to serve our customers around the world with high quality malt - and secure that the company with over 130 years of history will stay strong for many years to come“, says CEO Kasper Madsen.
Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark and Lithuania as well as two plants in Poland. The production capacity is 600 000 t/a and the turnover of the group is appr. 250 million euros and the company employ appr. 260 employees. Viking Malt is the largest malting company in Scandinavia, 5th largest in Europe and 9th in the world. It is the leading company in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
